2014
Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients
Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Re V. Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients. Clinical Infectious Diseases 2014, 58: 1449-1458. PMID: 24569533, PMCID: PMC4001286, DOI: 10.1093/cid/ciu097.Peer-Reviewed Original ResearchConceptsChronic hepatitis C virusAdvanced hepatic fibrosisHuman immunodeficiency virusHepatitis C virusAlcohol use categoriesAlcohol-related diagnosesHIV/HCV-coinfected patientsHepatic fibrosisAlcohol consumptionNonhazardous drinkingBinge drinkingHIV/HCV groupAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireVeterans Aging Cohort StudyFIB-4 indexAging Cohort StudyCross-sectional studyHCV groupHCV statusHIV-InfectedUninfected participantsChronic hepatitisUninfected patientsCohort studyLiver disease
2009
The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication
Freiberg MS, Leaf DA, Goulet JL, Goetz MB, Oursler KK, Gibert CL, Rodriguez-Barradas MC, Butt AA, Justice AC. The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication. Journal Of General Internal Medicine 2009, 24: 334-340. PMID: 19127386, PMCID: PMC2642578, DOI: 10.1007/s11606-008-0891-7.Peer-Reviewed Original ResearchConceptsNCEP/ATP III criteriaATP III criteriaHIV viral loadViral loadAdult Treatment Panel guidelinesHigher HIV viral loadFive-site studyLipid lowering medicationsVeterans Aging CohortHIV infection statusLipid-Lowering TherapyProspective observational cohortCross-sectional analysisHIV-HCVLowering therapiesModifiable mediatorsObservational cohortResultsThe prevalenceHIV infectionHIV statusPharmacy dataCardiovascular diseasePanel guidelinesMAIN OUTCOMELow prevalence